News

Angelini Pharma announced today the acquisition of Arvelle Therapeutics, the Swiss-based biopharmaceutical company focused on bringing innovative treatments to patients suffering from central nervous system disorders.

Ovid Therapeutics yesterday announced the topline results from the Company’s Phase III NEPTUNE clinical trial of OV101 (gaboxadol) for the treatment of Angelman syndrome.

In this issue, new stories and news, a focus on our commitment on mental health and our digital transformation, with the voices of the protagonists of our change.

November 25th marks the International Day for the Elimination of Violence Against Women, a global and severe issue that affects us all, women and men

A magazine designed to tell all about Angelini Pharma, its stories and those of its people, its most exciting projects and best practices.

The European Commission has approved a deal for GSK to sale its rights for ThermaCare® Heat Wraps to Angelini Pharma.

We are inside the 17,000 m2 of the Amuchina plant in Casella where 38 people produces the wide-spectrum disinfectant Amuchina.

Angelini Pharma has increased production of Amuchina at its Ancona plant and has focused the Casella factory on the production of disinfectants, outsourcing production of detergents.

Angelini Pharma has obtained the Top Employers Europe 2020 certification. The certification is awarded to companies that stand out for the implementation of significant, innovative and effective personnel management practices.

Angelini Farmacéutica takes 24 th place in the ranking of the most respected and recognised pharmaceutical companies in Spain.

The Summit brought together young and motivated psychiatrists from across Europe who are interested in digital developments and innovations in mental health.

Brussels, October 9th, 2019: Angelini Pharma’s international Public Affairs initiative “Headway2020 : A new roadmap in Mental Health” goes public ahead of the 27th World Mental Health Day at the European Parliament.

With healthcare policies, medical guidelines and not surprisingly prescriptions increasingly under scrutiny from both Health Authorities and budget holders, the goals for healthcare professional communications are rapidly changing.

The acquired products include BoxaGrippal® and Heumann.

Angelini supports the Italian Red Cross providing by medicines to people in Venezuela whose lives have been shattered by violence and instability.

On May 17 Angelini Pharma signed a deal with EUSA Pharma to be the exclusive distributor for Fotivda (Tivozanib), a product indicated for first line treatment of adult patients with advanced renal cell carcinoma (RCC)

The Board of Directors of Angelini Holding S.p.A., is pleased to announce that Pierluigi Antonelli has been appointed as the new CEO of Angelini Pharma, effective March 4th, 2019.